Skip to content

Clinical study on JPF-16 Capsules in Sexual Dysfunction in Females

An open label, multi-center, prospective clinical study to Evaluation of Efficacy and Safety of JPF-16 Capsules in Sexual Dysfunction in Females - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/06/008791
Enrollment
30
Registered
2017-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Female Sexual Dysfunction

Interventions

Intervention1: JPF-16 Capsule: JPF-16 Capsule contains Kapikacchu, Ashvagandha, Keshar, Akarkara, Shvet Musali, Shilajit, Ashok, Lodhra, Pradrantak loha, Puspadhanwa ras and others Dosage and Treatm

Sponsors

Chatarubhuj Pharmaceutical Co
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis of Female Sexual Interest/Arousal Disorder according to the DSM-5 criteria (2013) 2. Be involved in a stable relationship and have a partner 3. Healthy according to normal results of medical history, physical examination, laboratory values, and vital signs; exceptions may be made if the investigator considers an abnormality to be clinically irrelevant

Exclusion criteria

Exclusion criteria: 1.Subjects with major illnesses and sexual dysfunction due to anatomical, surgical or pharmacological causes 2.Subjects with history of major psychiatric disorder 3.Subjects with history of central nervous system disorders such as stroke, transient ischemic attacks or spinal cord injury or pelvic surgery 4.Subjects with hypotension or uncontrolled hypertension, uncontrolled diabetes, hepatic impairment, renal impairment or hematological disorders

Design outcomes

Primary

MeasureTime frame
Changes in sexual feelings and responses [assessment using Female Sexual Function Index (FSFI)] Timepoint: Day -7, Day 0, Day 14 and Day 28

Secondary

MeasureTime frame
1. Global assessment for overall improvement by the patient at the end of the study treatment. 2. Global assessment for overall improvement by the investigator at the end of the study treatment. 3. Assessment of Tolerability of study drug by assessing ADRs on study completion. 4. Assessment of Laboratory parametersTimepoint: Day -7, Day 0, Day 14 and Day 28

Countries

India

Contacts

Public ContactDr Sanjay Tamoli

Target Institute of Medical Education and Research

sanjaytamoli@hotmail.com9322522252

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026